Andere Sprachen InflaRx N.V.

Aktien

A2H7A5

NL0012661870

IFRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 08.05.2024			% 5 Tage	% 1. Jan.
1,2 ^USD	-3,23 %		-14,89 %	-26,38 %

14:44	InflaRx N.V. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
21.03.	Transcript : InflaRx N.V. - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	14:44
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update	13:31
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	30.04.
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed	26.04.
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K	25.04.
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	24.04.
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
InflaRx N : News Conference Call March 2024	21.03.
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	21.03.
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	19.03.
InflaRx Appoints Jan Medina as Head of Investor Relations	22.02.
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations	22.02.
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	25.01.
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904	04.01.
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	04.01.
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	06.11.
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	06.11.
Top Premarket Gainers	03.11.
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	01.11.
INFLARX N : UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 - Form 6-K	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen InflaRx N.V.

Aktien

A2H7A5

NL0012661870

IFRX

Andere Sprachen

Filter